Liminatus Pharma

LIMNNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$3.533 M

$2.63 -3.66%

Close of 6 Nov 2026

As of 6 Nov 2026, Liminatus Pharma (LIMN) has a market capitalization of $3.53M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

-$10.2M

Loss-making

Shares outstanding

67,160,362

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Other share classes

Liminatus Pharma lists more than one class of stock. Company figures above cover all classes combined.

LIMNW

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →

#156Black TitanBTTC$4.33M
#157PharmaCyte BiotechPMCB$4.03M
#158Liminatus PharmaLIMN$3.53M
#159Tessera Defense & Homeland SecurityHLSQ$3.22M
#160VivoSim LabsVIVS$2.41M

What if Liminatus Pharma were worth as much as…

Open the what-if tool →

Gold $28.2T

$21,021,967

Per share 7,993,143× higher

Bitcoin $1.53T

$1,137,462

Per share 432,495× higher

Apple $5.02T

$3,734,182

Per share 1,419,841× higher

Or at a round number

$5.00M $10.0M $20.0M $50.0M

Where these numbers come from

Share counts and financials for Liminatus Pharma are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.